Insulin-Sensitizing Properties of Decoctions from Leaves, Stems, and Roots of Cucumis prophetarum L

Zewdie Mekonnen1,2, Giuseppe Petito3, Getasew Shitaye2,3

  • 1Department of Biochemistry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa P. O. Box 9086, Ethiopia.

PubMed

Insights

Cucumis prophetarum L. decoctions show low cytotoxicity and potential to reduce insulin resistance in type 2 diabetes. Leaf, stem, and root extracts improved key insulin signaling proteins, offering new therapeutic avenues.

Area of Science:

  • Phytochemistry
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) involves insulin resistance and impaired beta-cell function, necessitating novel treatments due to existing therapy side effects.
  • Cucumis prophetarum L. is explored as a potential source for alternative diabetes therapies.

Purpose of the Study:

  • To evaluate the cytotoxicity and insulin-sensitizing properties of Cucumis prophetarum L. leaf, stem, and root decoctions.
  • To investigate the chemical composition of the decoctions and their effects on insulin signaling pathways.

Main Methods:

  • Cytotoxicity assessment on HepG2 and L6C5 cells.
  • Chemical characterization using UV-Vis, ATR-FTIR, and UHPLC-HRMS.
  • Western blot analysis of insulin signaling proteins (IRS-1, PKB/AKT, GSK-3β, AMPK, mTOR) in insulin-resistant L6 myoblasts.

Main Results:

  • Decoctions exhibited low cytotoxicity.
  • Stem and root decoctions significantly increased p-IRS-1, GSK3β, and p-AMPK levels.
  • Leaf decoction increased p-IRS-1 and p-AMPK, while decreasing p-GSK3β.
  • Root decoction reduced p-mToR levels, indicating reduced insulin resistance.

Conclusions:

  • Cucumis prophetarum L. decoctions demonstrate significant insulin-sensitizing effects.
  • These findings support further investigation of Cucumis prophetarum L. for managing diabetes and related metabolic disorders.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.1K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
185
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
152
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136